US approval for H. pylori treatment

The US FDA has given approval for Israel’s Redhill Biopharma to market its RHB-105 (Talicia) treatment for the treatment of Helicobacter pylori (H. pylori). It follows successful Phase 3 trials, as reported (here) previously. H. pylori affects some 2 million US patients.

https://www.timesofisrael.com/redhill-gets-fda-nod-for-drug-to-eradicate-gut-infection/

https://www.calcalistech.com/ctech/articles/0,7340,L-3773092,00.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.